Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC By Ogkologos - August 31, 2026 112 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the third pre-specified interim analysis of the OlympiA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Approves Alpelisib for PIK3CA-Related Overgrowth Spectrum April 13, 2022 Three-Drug Regimen Improves Protection against GVHD after Stem Cell Transplant July 14, 2023 Combination of Enzalutamide Plus Abiraterone Acetate and Prednisone Offers No Clinical... April 6, 2023 Intracranial Efficacy of Pembrolizumab in Patients with Brain Metastases June 20, 2023 Load more HOT NEWS A “Living Medicine:” Engineered E. coli Shrink Tumors in Mice The Future Front Line: Pre-Med During COVID-19 Potential for Larger Gene Panels to Increase the Number of Molecularly... Foodie Friday: Butternut Squash Macaroni Casserole
